Phase 1 N=41 Simplified Negative Pressure Wound Therapy
Wounds
Primary: Maintenance of Negative Pressure — 22.2 hours
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=217 Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept
Rheumatoid Arthritis · Plaque Psoriasis
Primary: Percentage of Participants With a Preference for Autoinjector A Versus Autoinjector B — 41.7; 43.5; 36.8 percentage of participants
Phase 2 N=55 Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Renal Cell Carcinoma
Primary: Overall Response Rate — 27 percentage of patients
Phase 3 N=158 A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma
Asthma
Primary: Baseline-adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC 0-6) Over the 12-week Treatment Period — 0.28; 1.11 L*hr — p=<0.0001
Phase 2 N=479 Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants
Malaria
Primary: Number of Subjects Reported With Serious Adverse Events (SAEs) — 5; 4; 5; 7 Participants
Phase 1 N=21 Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body
Chronic Myeloid Leukemia
Primary: Area Under Curve (AUC) Time Frame: Predose, 0.5,1,1.5,2,3,5,8,12,24,48,72hours Post-dose — 37256; 37206 mcg*hr/mL — p=<0.05
Phase 2 N=87 A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD) · Laymen Terminology Chronic Bronchitis and Emphysema
Primary: Patients Who Experienced at Least One Adverse Events(s) — 9; 10; 6 Participants
Phase 2 N=63 Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
Kidney Failure · Renal Failure
Primary: Pharmacokinetics of LCP-Tacro™ Tablets in the First 14 Days After Transplantation in Adult de Novo Kidney Recipients. — 78.57; 57.14 percentage of patients
Phase 2 N=24 Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function
Cystic Fibrosis
Primary: Cycle 1 and Cycle 2: Absolute Change From Cycle Baseline In Percent Predicted Forced Expiratory Volume In 1 Second (FEV1) After 2 Weeks of Treatment — 0.5828; 2.0898…
Phase 4 N=839 Pharmacogenomic Evaluation of Antihypertensive Responses 2
Hypertension
Primary: Change in Blood Pressure From Baseline to Treatment — -7.56; -7.97; -7.68; -11.70 mmHg — p=<0.0001
Phase 3 N=38 Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)
Exercise-Induced Bronchoconstriction (EIB)
Primary: Maximum Percentage Fall From Baseline in Forced Expiratory Volume in 1 Second (FEV1) up to 60 Minutes After the Exercise Challenge — 6.21; 22.38 percentage change from…
Phase 3 N=966 Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens
Moderate to Severe Plaque-type Psoriasis
Primary: For the Fixed Interval Group and the Start of Relapse (SoR) Group, the Percentage of Participants (Who Responded to Treatment at Week 12) Maintaining a 75% Improvement…
Phase 2 N=14 Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Stage IV Squamous Cell Carcinoma of the Hypopharynx · Stage IV Squamous Cell Carcinoma of the Larynx · Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity
Primary: Disease Control (i.e., Achievement of Complete Response, Partial Response, or Stable Disease) — 2; 9; 2 participants
Phase 2 N=14 Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma
Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma
Primary: Objective Response Rate Within the First 56 Weeks After the First Dose of Vandetanib — 38.5 percentage of participants
Phase 3 N=490 A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)
Diabetes Mellitus, Type 2
Primary: Model-adjusted Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — 0.25; -1.10; -1.30 Percentage of HbA1c in the blood — p=<0.0001